Background: Chronic inflammation has been implicated in the pathogenesis of several cancers, including lung and laryngeal cancer. The objective of the study is to elucidate the association between ICS use and diagnosis of lung and laryngeal cancer. Methods: A nested caseecontrol study based on the Korean national claims database included new adult users of inhaled medications between January 1, 2007, and December 31, 2010. Patients diagnosed with lung cancer or laryngeal cancer after enrollment were identified as cases and up to five control individuals matched for age, sex, diagnosis of asthma or COPD, Charlson Comorbidity Index scores, number of health care visits, and initiation date were selected. Results: From the 792,687 eligible cohort, 9177 individuals diagnosed with lung cancer were matched with 37,048 controls. Additionally, 408 laryngeal cancer patients and 1651 controls were matched. ICS use was associated with a decreased rate of lung cancer diagnosis [adjusted odds ratio (aOR), 0.79; 95% confidence interval (CI), 0.69e0.90]. The inverse association between ICS use and lung cancer risk was dose dependent (P < 0.0001 for the trend). However, no reduction in the risk of laryngeal cancer among ICS users was identified (aOR, 1.06; 95% CI, 0.62e1.18). Conclusion: The use of ICS is associated with a reduced risk of lung cancer but not of laryngeal cancer. ª
Introduction
Inhaled corticosteroids (ICS) uses a cornerstone treatment for chronic airway diseases, including asthma 1 and chronic obstructive pulmonary disease (COPD). 2 For patients with asthma, 3 ICS reduces asthma symptoms, 3 improves lung function and quality of life, 3 reduces the frequency and severity of exacerbations, 4 and decreases asthma mortality. 5 Among patients with COPD, ICS improves quality of life, 6 and reduces symtoms. 6, 7 The benefit of ICS in patients with asthma 8 or COPD 9,10 is based mainly on its anti-inflammatory effects. Given that chronic inflammation has been implicated in the pathogenesis of several cancers, including lung cancer and head and neck cancers, 11, 12 the chemopreventive efficacy of inhaled budesonide was tested for its effect on lung carcinogenesis in mice and was reported to be effective. 13 Additionally, a report proposing that ICS may prevent development of lung cancer was published recently, 14 although the association between ICS and laryngeal cancer was not investigated.
Patients with COPD and asthma use ICS frequently and are a high risk group for lung and laryngeal cancers. 15e17 In this context, we examined the association between ICS use and diagnoses of lung and laryngeal cancers by analyzing the Health Insurance Review and Assessment Service database, which includes records for almost all South Koreans.
Material and methods

Source of data
We used the database of the Health Insurance Review and Assessment Service (HIRA, Seoul, South Korea), a government-affiliated agency responsible for examining the accuracy of claims quality for National Health Insurance (NHI, which covers approximately 96.6% of the entire 48.6 million South Korean population) and National Medical Aid (covering approximately 3.5% of the South Korean population). The NHI database includes the entire South Korean population as well as registered foreign-nationality residents as a compulsory insurance system, with exceptions for cases applicable to the National Medical Aid program or foreign military personnel. 18 The HIRA database contains information on demographics and all medical services rendered, along with the diagnostic code (ICD-10 code) and all prescription medications dispensed. Values in key fields such as drug name, quantity, date dispensed, and duration are missing or out of range in <0.5% of records. These databases have been used in previous studies. 
Study design
A nested caseecontrol study was conducted based on the HIRA database. The source population consisted of all individuals who were dispensed at least one of the following inhaled respiratory medications between January 1, 2007, and December 31, 2010 : ICS, (beclomethasone, budesonide, triamcinolone, ciclesonide, fluticasone, or flunisolide), short-acting inhaled b 2 -agonists (SABA; salbutamol, fenoterol, procaterol, or terbutaline), long-acting inhaled b 2 -agonists (LABA; salmeterol or formoterol), short-acting inhaled muscarinic antagonists (SAMA; ipratropium), long-acting inhaled muscarinic antagonists (LAMA; tiotropium), a combination of SABA and SAMA (ipratropium/salbutamol), or a combination of LABA and ICS (budesonide/formoterol, fluticasone/salmeterol).
The eligible cohort of new users of inhaled respiratory medication was identified from all individuals who had a prescription for an inhaled respiratory medication for 30 days or longer between January 1, 2007, and December 31, 2010 . The date of the first use of the above inhaled respiratory medications was called the initiation date. Individuals who had had a prescription for inhaled respiratory medication for 30 days or longer or who had any of the ICD-10 cancer diagnoses (C00eC97, D00eD09) within the year prior to the initiation date were excluded. Additionally, individuals <20 years of age or >120 years were also excluded. The eligible individuals were monitored until the diagnosis of lung cancer or head and neck cancer or until December 31, 2010 .
The protocol of this study was approved by the ethics review committee of the National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea.
Case definition
Within the eligible cohort, we identified case individuals based on ICD-10 diagnoses of lung cancer (C33eC34, D02.1, D02.2) or head and neck cancer other than thyroid cancer (C00eC14, C30eC32, D00.0, D02.0, D02.3) that occurred after the initiation date of the inhaled respiratory medications. The index date was defined as the date of first assignment of the above ICD-10 codes.
Control individuals
For each case individual, up to five control individuals, who were randomly matched for age (within 1 year), sex, diagnosis of asthma (J45eJ46) or COPD (J41eJ44), number of health care utilizations (number of hospitalizations [AE1] and number of outpatient visits [AE3]), and initiation date (within 15 days), were selected without replication from among individuals without an ICD-10 diagnosis of lung or head and neck cancer. The index date for the controls was defined as the index date for their matched case.
Inhaled corticosteroid exposure
ICS included orally inhaled beclomethasone, budesonide, triamcinolone, ciclesonide, fluticasone, or flunisolide, whether dispensed alone or in a combination inhaler with an inhaled b 2 -agonist. The estimation of equivalencies was chosen based on relative topical potency and what experts consider to be comparable doses according to the National Asthma Education and Prevention Program Expert Panel report 3, 24 the Canadian Asthma Consensus Statement, 25 and the Global Strategy for Asthma Management and Prevention 2010 (updated). 26 Accordingly, the equivalent doses for ICS were 100 mg beclomethasone, 50 mg beclomethasone HFA, 80 mg budesonide, 200 mg triamcinolone, 32 mg ciclesonide, 50 mg fluticasone, and 200 mg flunisolide. All doses were converted to fluticasone equivalents and average daily doses were categorized as high (fluticasone, 1000 mg/d or more), moderate (fluticasone, 500e999 mg/d), and low (fluticasone, <500 mg/d) according to defined daily doses of the most recent prescription in the 60 days before the index date. 27, 28 Total number of prescribed ICS was counted and an ICS user was defined as current if ICS prescriptions for 30 days or longer were identified for the period within 90 days before the index date. If ICS prescriptions for 30 days or longer were identified for the period between 91 and 365 days before the index date, the patients were classified as past users. If the ICS prescriptions were for shorter than 30 days, patients were regarded as non-users.
Covariates
We adjusted for inhaled respiratory medication other than ICS, overall comorbidity, and cumulative dose of oral corticosteroids (OCS) used. Inhaled respiratory medication other than ICS encompassed SABA, LABA, SAMA, SABA/SAMA, and LAMA which were used within 1 year prior to the index date. Overall comorbidity was adjusted using the Charson Comorbidity Index, a validated risk-adjustment scoring system used in outcomes researches. 29, 30 The cumulative doses of OCS used during 1 year before the index date were calculated and used for adjusting the cancer risk according to ICS use. The OCS prescriptions were converted to prednisone using the following equivalent doses: 1 mg hydrocortisone (cortisol), 1.6 mg cortisone, 4 mg prednisone, 5 mg prednisolone, 4 mg methylprednisolone, 4 mg triamcinolone, 0.03 mg betamethasone, and 0.03 mg dexamethasone. 31 Smoking status was not included as a covariate because the HIRA database does not include smoking status.
Statistical analysis
Baseline characteristics including, age, sex, comorbidities, number of health care utilizations, and inhaled respiratory medication use of cases and control patients were summarized by descriptive statistics such as proportion, mean, standard deviation, median, and interquartile range. The association between the use of inhaled respiratory medication and lung or head and neck cancer were investigated by conditional logistic regression. Continuous variables were categorized into appropriate categorical variables based on the distributions. Likelihood ratio tests were used to examine the goodness of fit of the model, and no significant lack of fit was found. Adjusted odd ratios (aORs) are presented with 95% confidence intervals (CIs) and a P-value. To explore the doseeresponse relationship, we initially divided the distribution of the cumulative ICS dose into <15,000 mg, 15,000 mg, 15,001e29,999 mg, 30,000 mg, and >30,000 mg because patients with cumulative ICS dose of 15,000 mg or 30,000 mg were common. In addition, we divided the group with ICS 15,000 mg into 5000 mg and 5000e14,999 mg because more than 20% of patients were classified into the group with ICS dose <15,000 mg. Tests for trends were performed using the medians of each group as continuous variables in a linear logit model.
A protopathic bias can occur when early symptoms of undetected cancer could affect the use of ICS. 32 We performed a sensitivity analysis to explore the impact of protopathic bias using 3-, 6-, and 12-month lag-time analysis. The risk of cancer according to ICS was calculated after ignoring the use of ICS within the lag time prior to the index date.
All data manipulation and statistical analyses were performed using SAS 9.1.3 (SAS Institute, Cary, NC, USA). A P-value <0.05 was considered statistically significant.
Results
We identified 1,341,229 individuals with prescriptions for inhaled respiratory medications with a duration of 30 days or longer between January 1, 2007, and December 31, 2010 . Among them, 203,230 individuals who had had previous prescriptions for inhaled respiratory medications for 30 days or longer during the year before the current initiation of inhaled respiratory medication were excluded. 
Patients with lung cancer and controls
For the 9177 individuals with lung cancer, we identified 37,048 controls matched for age, sex, a diagnosis of asthma or COPD, Charlson Comorbidity Index scores, and the number of hospital visits (Fig. 1) . 68.6% of lung cancer patients and 68.1% of controls were male. The mean ages of the patients with lung cancer and of controls were 68.7 and 68.1 years, respectively. COPD and asthma were the most common respiratory diseases among them. Regarding the Charlson Comorbidity Index, 26.6% of patients with lung cancer and 20.7% of controls had scores of 4 or higher. The number of hospitalizations, outpatient visits, and ER visits were similar between the groups ( Table 1) .
Impact of inhaled corticosteroids on lung cancer risk
After adjusting for differences in the covariates, ICS use was associated with a decreased rate of lung cancer diagnosis (aOR, 0.79; 95% CI, 0.69e0.90). Additionally, the association between ICS use and a decreased risk of lung cancer was dose dependent (P < 0.001for the trend; Table  2 ). This association was maintained in sensitivity analyses using 3-and 6-month lag-time analyses (Table 3) .
Although LABA use was not associated with the risk of lung cancer, LAMA use was associated with an increased risk of lung cancer (aOR, 1.10; 95% CI, 1.02e1.19). However, the association between LAMA use and lung cancer disappeared in the sensitivity analyses (Table 3) .
Patients with laryngeal cancer and controls
For the 408 individuals with laryngeal cancer, we identified 1651 matched for age, sex, asthma or COPD, Charlson Comorbidity Index score, and number of hospital visits.
In total, 83.1% of patients with laryngeal cancer and 83.3% of controls were male. The mean ages of the cases and controls were 67.2 and 66.8 years, respectively. Asthma and COPD were the most common diseases. In total, 26.7% of the cases and 19.2% of the controls had scores of 4 or higher on the Charlson Comorbidity Index. The number of hospitalizations, outpatient visits, and ER visits were similar between the groups (Table 1) . 0.53e1.13) were not associated with the risk of laryngeal cancer. Even with a cumulative ICS dose greater than 30,000 mg, no reduction in the risk of laryngeal cancer was observed (aOR, 0.84; 95% CI, 0.45e1.55; Table 4 ). Sensitivity analyses using 3-and 6-month lag-time analyses showed similar results (Table 5) .
Impact of inhaled corticosteroids on laryngeal cancer risk
Discussion
The global burden of cancer continues to increase largely because of the aging and growth of the world population and the increasing adoption of cancer-causing behaviors, particularly smoking in economically developing countries. The lung is the leading cancer site in males, and lung cancer accounts for 17% of all new cancer cases and 23% of total cancer deaths. 33 It is also common in females as the fourth most common cancer. In addition, nasopharyngeal cancer is the twenty-fourth most common cancer in the world. 33 Patients with COPD 15, 16 and asthma, 17 are a high risk group for development of lung cancer. Our results showed that ICS use reduces the risk for lung cancer but not for laryngeal cancer.
The inverse relationship between ICS use and a diagnosis of lung cancer can be understood through the antiinflammatory effects of steroids. The concept that inflammation is a critical component of tumor progression has been widely accepted. Many cancers arise from sites of infection, chronic irritation, and inflammation. Inflammatory conditions are present before a malignant change The links between chronic inflammation and lung cancer is well known. 35 In addition, allergic respiratory inflammation promotes the recruitment of circulating tumor cells in mice, thus promoting lung metastasis. 36 Corticosteroids, the most potent anti-inflammatory drugs, could suppress the chronic inflammatory process and, subsequently, the tumor-promoting effects of inflammation. In fact, nonsteroidal anti-inflammatory drugs, another potent class of anti-inflammatory drugs, are proposed to have a protective effect on lung cancer in a meta-analysis. 37 A previous study exploring the association between ICS use and development of lung cancer using a cohort of 10,474 US veterans with COPD suggested a reduction in lung cancer with ICS use.
14 That result was confirmed in our study, which analyzed a cohort of 792,687 new users of inhaled respiratory medication.
Several reasons exist to expect the same protective effect of ICS on laryngeal cancer. Lung cancer and laryngeal cancer have common predisposing factors, smoking, the most prominent environmentally predisposing factor. 38 Smoking is a potent inducer of inflammation and plays a key role in carcinogenesis throughout the respiratory tract. 39, 40 The links between chronic inflammation and both lung cancer 35 and laryngeal cancer 41 are well established. Additionally, deposition of some portion of the inhaled medication in upper airways is inevitable. 42 However, we failed to identify an association between ICS use and development of laryngeal cancer ( Table 5) .
The differential effect of ICS on the development of lung cancer or laryngeal cancer might be explained by the amount of inhaled ICS deposited. Although more than half of the emitted dose deposits are in the upper airway, most of the drugs are removed from the oral cavity, oropharynx, or larynx by rinsing and swallowing. 43 Given that the preventive effect of ICS on lung cancer was dose dependent in our study, the amount of ICS deposited on the larynx might be lower than the threshold for a preventive effect on carcinogenesis in laryngeal cancer.
ICS use is associated with various systemic adverse effects such as diabetes, 44 adrenal insufficiency, 45 osteoporosis/fracture, 46 and cataracts. 47 Considering these unwanted adverse effects, reduction of ICS side effects by combining ICS with other inhaled respiratory medications in asthma 48 and use of ICS in patients with more advanced COPD 2 are recommended. However, our data suggests the presence of unintended beneficial effects of ICS. How to adopt this beneficial effect should be investigated, if it is confirmed in future studies.
Interestingly, LAMA use showed a positive association with lung cancer in our study. However, in the sensitivity analysis, ignoring the use of ICS within the lag time (3 or 6 months) prior to the index date, the statistical significance of the association disappeared (Table 3) . The association between LAMA use and lung cancer in the original analysis might be due to 'protopathic bias' 32 rather than to a true harmful effect. In addition, the risk of lung cancer did not decrease in patients with the highest cumulative dose of ICS. However, sensitivity analysis resulted in decreased risk of lung cancer among highest cumulative dose ICS users. These results also raise the possibility of protopathic bias.
To appreciate our results, the strengths and limitations of this study must be acknowledged. One of the main strengths of this study was that it was based on a nationwide database, which minimized the likelihood of selection bias. Additionally, we avoided protopathic bias, which occurs when early symptoms of undetected cancer affect the use of ICS, through a sensitivity analysis using 3-and 6-month lag-time analysis. The most important limitation of this study was that smoking status of inhaled respiratory medications users was not available. Selecting controls from users of other inhaled respiratory medications and matching important variables such as age, sex, asthma, or COPD, Charlson Comorbidity Index scores, and health care utilization could minimize the confounding effects of smoking on the results of this study.
In conclusion, exposure to ICS was associated with a reduced risk of lung cancer but not laryngeal cancer. Confirmation of these findings in different cohorts and discussion on proper application of the findings to clinical practice are needed.
